PBAC's latest decision on Biologics (etanercept, infliximab, adalimumab, ustekinumab, secukinumab, ixekizumab, guselkumab, tildrakizumab): Noted (2020). Considered for Chronic plaque psoriasis in patients with baseline PASI ≥ 12 to ≤ 15 who have failed to achieve adequate response to at least two conventional therapies (phototherapy, methotrexate, ciclosporin, or acitretin).
PBAC outcome
Noted
2020
ICER (AUD/QALY)
$200k/QALY
Range: $105k/QALY–$200k/QALY
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Patients with chronic plaque psoriasis with baseline PASI ≥ 12 to ≤ 15 who have failed at least two conventional therapies (phototherapy, methotrexate, ciclosporin, or acitretin).
Therapy area
Dermatology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
PASI 75
Comparator
placebo
Economic model
CUA
Eligible patients/year
4,405
ICER note
Base case ICER for PASI ≥12 to ≤15 population. Existing ICER for PASI >15 was $15,000–$45,000/QALY.